Matthew Longo

Merritt College — United States

Medicine · Health Sciences

3h-index41citations64works0.22yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mosquito-borne diseases and control(31), Virus-based gene therapy research(19), Neuroblastoma Research and Treatments(14), Ovarian cancer diagnosis and treatment(5), Lung Cancer Treatments and Mutations(3)

Publications64 total

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Brain Pathology·2025Open Access

A presença da educação ambiental na educação infantil: estudo em creches de Santo André/SP – Brasil

RCMOS - Revista Científica Multidisciplinar O Saber·2025Open Access

Serum Anti-Müllerian Hormone does not predict adverse perinatal outcomes in a cohort of women diagnosed with recurrent pregnancy loss

Italian Journal of Gynaecology and Obstetrics·2024Open Access

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 7 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Data from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

FIGURE 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

Supplementary Figure 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

2024Open Access

page 1 of 4Next →

Frequent Co-authors

Jeanne K. Brooks(22), Joseph Mazar(21), Matthew Peloquin(21), Rosa Rosario(21), Emma Sutton(21), Dennis Drehner(21), Tamarah J. Westmoreland(21), A. Lembo(5), Fabio Ghezzi(5), Jvan Casarin(5), M Dri(4), N Oltolina(4), Mauro Papotti(3), Valeria Artuso(3), Silvia Novello(3), Giorgio V. Scagliotti(3), A. Arcoria(2), Emanuele Maccarone(2), Giuseppe Parisi(2), Elisa Bacillo(2)